Laboratory Corporation of America Holdings (LH) continues to display strong and consistently positive financial performance. The company has been outperforming projections for several quarters, leading to spectacular growth for the stock, which stands 67% higher than it did five years ago. Wealth management companies are consequently increasing their stake in the company. The company recently announced the acquisition of a number of selected assets from both Invitae and BioReference Health's Diagnostics Business, displaying its aggressive growth strategy. Labcorp continues to expand its testing capabilities and has recently developed a test for preeclampsia in pregnant women while continually innovating and introducing new portfolio assets such as their weight loss management portfolio. Despite this, there are doubts surrounding executive compensation packages. Still, the company's high-performance results in analysts rating the stock a 'moderate buy.' The company's overall strategy appears to be focused on growth through both acquisition and innovation in diagnostics.
Laboratory Corporation of America Holdings LH News Analytics from Thu, 28 Sep 2023 07:00:00 GMT to Sun, 18 Aug 2024 20:43:45 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor -3
